BC007

BC007 is an innovative bispecific antibody targeting Claudin 18.2 (CLDN18.2) and CD47, developed by Dragon Boat Pharmaceutical in collaboration with Sanyou Biopharmaceuticals. It is designed for the treatment of advanced solid tumors, specifically those expressing CLDN18.2, such as gastric, pancreatic, and colon cancers. The drug's mechanism of action involves dual targeting: the anti-CLDN18.2 arm binds to tumor cells to facilitate direct targeting, while the anti-CD47 arm blocks the 'don't eat me' signal, thereby preventing immune evasion and enhancing macrophage-mediated phagocytosis. By utilizing a bispecific format, BC007 aims to improve tumor selectivity and potentially mitigate the hematologic toxicities often associated with systemic CD47 blockade. In June 2022, the IND application for BC007 was accepted by China's National Medical Products Administration (NMPA), and it is currently undergoing Phase 1 clinical evaluation.